Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Driven Immunosuppression

Cantargia AB ( (SE:CANTA) ) has provided an update.

Cantargia AB announced new preclinical data published in Cancer Discovery, demonstrating that targeting IL1RAP with nadunolimab can counteract tumor-driven systemic immunosuppression. The findings suggest that nadunolimab could enhance the efficacy of cancer vaccines and improve outcomes in cancer treatment by reducing immunosuppressive cells and enhancing T cell responses. Clinical data supports these findings, showing a significant decrease in neutrophils and improved prognostic indicators in patients treated with nadunolimab, highlighting its potential to improve immunotherapy outcomes.

More about Cantargia AB

Cantargia AB is a biotechnology company that develops antibody-based treatments for life-threatening diseases, focusing on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. The company’s primary oncology program involves the antibody nadunolimab (CAN04), studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia is also developing CAN10, targeting serious autoimmune and inflammatory diseases.

YTD Price Performance: -2.61%

Average Trading Volume: 2,500

Technical Sentiment Signal: Buy

Current Market Cap: €36.77M

For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.